A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 190
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : VLCFA
Long Form : very long chain fatty acids
No. Year Title Co-occurring Abbreviation
1984 Adrenoleukodystrophy in Israel: a genetic, clinical and biochemical study. ALD, AMN
1984 Bone marrow transplant in adrenoleukodystrophy. ALD, BMT
1987 Fatty acid synthesis in mitochondria from Saccharomyces cerevisiae. ---
1987 Gas chromatography-electron impact-mass spectrometry (GC-EI-MS) analysis of saturated fatty acid compositions in formalin-fixed human tissues. ALD, GC-EI-MS, GC-EI-MS
1987 Very long chain fatty acid beta-oxidation by rat liver mitochondria and peroxisomes. ---
1990 Central nervous system malformations and white matter changes in pseudo-neonatal adrenoleukodystrophy. ---
1990 Peroxisomal disorders: complementation analysis using beta-oxidation of very long chain fatty acids. ---
1990 Two siblings with phenotypes mimicking peroxisomal disorders but with discordant biochemical findings. ---
1990 [Familial spastic paraparesis: phenotypic variant of adrenoleukodystrophy]. ---
10  1990 [X-chromosomal adrenoleukodystrophy. A peroxisomal disease important for differential diagnosis in the internal medicine-neurological field]. ---
11  1991 Fatty acid composition of human myelin proteolipid protein in peroxisomal disorders. PLP
12  1992 Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. ALD
13  1992 Prenatal diagnosis in high risk pregnancies for Zellweger syndrome. ---
14  1992 [Peroxisomal neurologic diseases and Refsum disease: very long chain fatty acids and phytanic acid as diagnostic markers]. ALD/AMN, BMT, PHYT
15  1993 Characterization of X-linked adrenoleukodystrophy in different biological specimens from ten Portuguese families. ALD, EBV
16  1993 Complementation analysis of patients with intact peroxisomes and impaired peroxisomal beta-oxidation. ---
17  1993 Diagnosis of peroxisomal disorders with neurological involvement. PHYT
18  1993 Unusual orthochromatic leukodystrophy with epitheloid cells (Norman-Gullotta): increase of very long chain fatty acids in brain discloses a peroxisomal disorder. ---
19  1993 [Clinical types of adrenoleukodystrophy]. ALD
20  1993 [Symptomatic heterozygotic adrenoleukodystrophy in adults. 10 cases]. ---
21  1994 An improved method for quantification of very long chain fatty acids in plasma. GLC
22  1994 An index case of adrenomyeloneuropathy in a Chinese man. ADL, AMN
23  1994 Effect of exogenous fatty acids with greater than 22 carbon atoms (very long chain fatty acids) on superoxide production by human neutrophils. LCFA
24  1994 High dose immunoglobulin IV treatment in adrenoleukodystrophy. ALD, GTOE
25  1994 Resistance to erucic acid as a selectable marker for peroxisomal activity: isolation of revertants of an infantile Refsum disease cell line. IRD
26  1994 The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. ALDP
27  1994 [Adrenomyeloneuropathy. A frequent cause of Addison's disease]. AMN
28  1995 Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. ABC, ALD, AMN
29  1995 Clinical approach to inherited peroxisomal disorders. NALD, RCDP, ZS
30  1995 Distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies. ---
31  1995 Peroxisomal activation of long- and very long-chain fatty acids in the yeast Pichia pastoris. LCFA, pas, VLCS, X-ALD
32  1995 Pre- and postnatal diagnosis of peroxisomal disorders using stable-isotope dilution gas chromatography--mass spectrometry. CSF, GC-MS
33  1995 X-linked adrenoleukodystrophy presenting as neurologically pure familial spastic paraparesis. FSPs
34  1996 Autonomic neuropathy in a patient with adrenomyeloneuropathy. ALD, AMN
35  1996 Carrier identification of X-linked adrenoleukodystrophy by measurement of very long chain fatty acids and lignoceric acid oxidation. ALD
36  1996 Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal beta-oxidation defects. ---
37  1996 Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. ---
38  1996 [Examination of very long chain fatty acids in diagnosis of x-linked adrenoleukodystrophy]. AMN, X-ALD
39  1997 Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. ALD, ALDP
40  1997 Effects of exogenous hexacosanoic acid on biochemical myelin composition in weaning and post-weaning rats. ALD, CNPase, GL, HA, MBP
41  1997 Exogenous lipids in myelination and myelination. CNS, EFA, MBP
42  1997 Progression of X-linked adrenoleukodystrophy under interferon-beta therapy. ALD, INFb
43  1997 Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. ABC, ALD, CNS
44  1998 Adrenoleukodystrophy: unusual clinical and radiographic manifestation. ---
45  1998 Cytokine-induced accumulation of very long-chain fatty acids in rat C6 glial cells: implication for X-adrenoleukodystrophy. LPS, NO, X-ALD
46  1998 Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. ALD
47  1998 Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. HMG-CoA, X-ALD
48  1998 Restoration of PEX2 peroxisome assembly defects by overexpression of PMP70. CHO, PBD
49  1998 Therapy for X-adrenoleukodystrophy: normalization of very long chain fatty acids and inhibition of induction of cytokines by cAMP. IL-1beta, PKA, TNF-alpha, X-ALD
50  1998 [X-linked adrenoleukodystrophy--2 case reports]. ALD, AMN
51  1999 Adrenoleukodystrophy protein enhances association of very long-chain acyl-coenzyme A synthetase with the peroxisome. ALD, ALDP, VLACS
52  1999 Cerebral inflammation in X-linked adrenoleukodystrophy. AMN, CER, MS, VLCS, X-ALD
53  1999 Prenatal diagnosis of X-linked adrenoleukodystrophy combining biochemical, immunocytochemical and DNA analyses. AFC, X-ALD
54  1999 Very long-chain fatty acids in Rett syndrome. RS
55  1999 Zellweger syndrome in Saudi Arabia and its distinct features. DHAPATase, ZS
56  1999 [Adrenoleukodystrophy: genetics, phenotypes, pathogenesis, and treatment]. ---
57  2000 Cholesterol metabolsim defect associated with Conradi-Hunerman-Happle syndrome. CHS, DHA, DHCA, PUFA, RBC, THCA
58  2000 Lovastatin does not correct the accumulation of very long-chain fatty acids in tissues of adrenoleukodystrophy protein-deficient mice. ALDP, X-ALD
59  2000 Rolipram does not normalize very long-chain fatty acid levels in adrenoleukodystrophy protein-deficient fibroblasts and mice. X-ALD
60  2000 Therapeutic plasma exchange in treatment of adrenoleukodystrophy. ALD, TPE
61  2000 Very long-chain acyl-CoA synthetases. Human "bubblegum" represents a new family of proteins capable of activating very long-chain fatty acids. bgm, VLCS
62  2001 ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. AMN, CCALD, X-ALD
63  2001 Adult-onset adrenoleukodystrophy: a clinical and neuropsychological study. ALD, AMN
64  2001 Decreasing serum VLCFA levels in ageing X-ALD female carriers. ---
65  2001 Restoring the DHA levels in the brains of Zellweger patients. DHA, MRI, PUFA
66  2001 Th 1 cytokine production by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy. ALD, AMN, CNS, LPS, PBMC, PHA
67  2001 [Endocrine disease in adrenoleukodystrophy]. GTE, GTO
68  2002 Molecular analysis of genomic DNA allows rapid, and accurate, prenatal diagnosis of peroxisomal D-bifunctional protein deficiency. ---
69  2002 Mouse very long-chain acyl-CoA synthetase in X-linked adrenoleukodystrophy. VLCS, Vlcs, X-ALD
70  2002 [Clinical heterogeneity of X-linked adrenoleukodystrophy ]. X-ALD
71  2002 [X-linked adrenoleukodystrophy--case reports of 4 patients in a family]. ALD, AMN
72  2003 A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy. VLCS, X-ALD
73  2003 Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. ESI-MS, GC, X-ALD
74  2003 Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy. X-ALD
75  2003 Effects of the testosterone metabolite dihydrotestosterone and 5 alpha-androstan-3 alpha,17 beta-diol on very long chain fatty acid metabolism in X-adrenoleukodystrophic fibroblasts. DHT, X-ALD
76  2003 Multifunctional acetyl-CoA carboxylase 1 is essential for very long chain fatty acid elongation and embryo development in Arabidopsis. ACCase, TAG
77  2003 Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. ALD
78  2003 [Analysis on mutation of adrenoleukodystrophy gene in exon 1 and exon 5]. ALD
79  2003 [Clinical characteristics of X-linked adrenoleukodystrophy]. ALD, MRI
80  2004 Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. CAT, GPx, SOD, TAR, TBARS, TRAP, X-ALD
81  2004 Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes. LDL
82  2004 X-linked adrenoleukodystrophy: role of very long-chain acyl-CoA synthetases. VLACS, X-ALD
83  2005 Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency. ---
84  2005 Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone. 17 alpha-OHP, ALD, AMN, DHEAS
85  2005 Adrenomyeloneuropathy. ---
86  2005 Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. X-ALD
87  2005 Very long chain fatty acids (policosanols) and phytosterols affect plasma lipid levels and cholesterol biosynthesis in hamsters. HDL-C, LT, PS, TC
88  2006 Cerebral childhood and adolescent X-linked adrenoleukodystrophy. Clinical presentation, neurophysiological, neuroimaging and biochemical investigations. ---
89  2006 Fatty acid elongases in mammals: their regulation and roles in metabolism. FAS, PUFA
90  2006 Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. X-ALD
91  2006 Substrate specificity of Arabidopsis 3-ketoacyl-CoA synthases. FAE, KCS
92  2006 The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. CAT, GPx, SOD, TAR, TBARS, X-ALD
93  2006 Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPARalpha). BCFA, PPARalpha
94  2007 Composition of alkyl esters in the cuticular wax on inflorescence stems of Arabidopsis thaliana cer mutants. Ws
95  2007 Dehydroepiandrosterone up-regulates the Adrenoleukodystrophy-related gene (ABCD2) independently of PPARalpha in rodents. ALDRP, X-ALD
96  2007 Depletion of ceramides with very long chain fatty acids causes defective skin permeability barrier function, and neonatal lethality in ELOVL4 deficient mice. ELOVL4
97  2007 Down-regulation of fatty acid synthase increases the resistance of Saccharomyces cerevisiae cells to H2O2. FAS
98  2007 Immunopathogenesis of adrenoleukodystrophy: current understanding. HSCT
99  2007 Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy. AMN, CCER, TAS, TAS, TBARS, X-ALD
100  2007 Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. scd1
101  2007 X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. X-ALD
102  2007 [A man with progressive spastic paraparesis]. ---
103  2007 [The clinical value of measuring plasma level of very long chain fatty acids in Addison disease]. X-ALD
104  2008 Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. CCALD, X-ALD
105  2008 Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect. CCER, LO, X-ALD
106  2008 Investigational methods for peroxisomal disorders. GC
107  2008 Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy. HTZ, TAR, TAS, TBARS, X-ALD
108  2009 Assessment of very long-chain fatty acids as complementary or alternative natural fecal markers to n-alkanes for estimating diet composition of goats feeding on mixed diets. ---
109  2009 Fast diffusion of very long chain saturated fatty acids across a bilayer membrane and their rapid extraction by cyclodextrins: implications for adrenoleukodystrophy. ---
110  2009 HOS3, an ELO-like gene, inhibits effects of ABA and implicates a S-1-P/ceramide control system for abiotic stress responses in Arabidopsis thaliana. ---
111  2009 Lessons from the gonadotropin-regulated long chain acyl-CoA synthetase (GR-LACS) null mouse model: a role in steroidogenesis, but not result in X-ALD phenotype. GR-LACS, LC, X-ALD
112  2009 Mutations in the fatty acid transport protein 4 gene cause the ichthyosis prematurity syndrome. FATP4, IPS
113  2009 Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism. PUFA
114  2009 [Primary adrenal insufficiency as the form of onset of adrenoleukodystrophy in a 4-year-old boy]. ---
115  2010 Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes. ---
116  2010 Biochemical aspects of X-linked adrenoleukodystrophy. ATP, ELOVL1, X-ALD
117  2010 General aspects and neuropathology of X-linked adrenoleukodystrophy. AMN, ATP, GM-CSF, IL, X-ALD
118  2010 Genetics and molecular pathology of Stargardt-like macular degeneration. ELOVL4
119  2010 Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. AMN, cALD, X-ALD
120  2010 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. ALDP, X-ALD
121  2010 Typical cMRI pattern as diagnostic clue for D-bifunctional protein deficiency without apparent biochemical abnormalities in plasma. DBP, DBPD
122  2010 Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. VPA, X-ALD
123  2010 Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy. 5-LOX, cALD
124  2010 X-linked adrenoleukodystrophy presenting as Addison's disease. ACTH, HSCT, X-ALD
125  2011 Adrenoleukodystrophy. ALD
126  2011 Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. ROS, X-ALD
127  2011 Changes in carnitine octanoyltransferase activity induce alteration in fatty acid metabolism. CROT
128  2011 Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy. ALD, cALD, CNS, HSCT
129  2011 FATP4 missense and nonsense mutations cause similar features in Ichthyosis Prematurity Syndrome. FATP4, IPS
130  2011 Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible? ALD/AMN
131  2011 Molecular analysis of ABCD1 gene in Indian patients with X-linked adrenoleukodystrophy. CSGE, CV, PND, X-ALD
132  2011 Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. LA
133  2011 Substrate specificity overlap and interaction between adrenoleukodystrophy protein (ALDP/ABCD1) and adrenoleukodystrophy-related protein (ALDRP/ABCD2). ABC, X-ALD
134  2011 Two novel PEX1 mutations in a patient with Zellweger syndrome: the first Korean case confirmed by biochemical, and molecular evidence. PBD, ZS
135  2011 [X-linked adrenoleukodystrophy or the trap of making commonplace of child's psycho-cognitive disorders]. X-ALD
136  2012 Adrenoleukodystrophy: a forgotten diagnosis in children with primary Addison's disease. X-ALD
137  2012 Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. ABC, X-ALD
138  2012 Evidence of oxidative stress in very long chain fatty acid--treated oligodendrocytes and potentialization of ROS production using RNA interference-directed knockdown of ABCD1 and ACOX1 peroxisomal proteins. P-NALD, ROS, SOD, X-ALD
139  2012 Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases? AD, HD, PD, X-ALD
140  2012 X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. X-ALD
141  2012 X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. ABC, AMN, X-ALD
142  2013 Adrenomyeloneuropathy presenting with adrenal insufficiency. ALD, AMN
143  2013 Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes. CAPE, X-ALD
144  2013 Child neurology: Zellweger syndrome. ZS
145  2013 Exome sequencing released a case of X-linked adrenoleukodystrophy mimicking recessive hereditary spastic paraplegia. HSP
146  2013 Molecular characterization of X-linked adrenoleukodystrophy in a Tunisian family: identification of a novel missense mutation in the ABCD1 gene. X-ALD
147  2013 Molecular species of phospholipids with very long chain fatty acids in skin fibroblasts of Zellweger syndrome. X-ALD
148  2013 The impact of a ketogenic diet and liver dysfunction on serum very long-chain fatty acids levels. ---
149  2014 A Korean boy with atypical X-linked adrenoleukodystrophy confirmed by an unpublished mutation of ABCD1. PCR, X-ALD
150  2014 Abcd2 is a strong modifier of the metabolic impairments in peritoneal macrophages of ABCD1-deficient mice. ABC, MPMPhi, X-ALD
151  2014 Adrenomyeloneuropathy with bulbar palsy: A rare association. ALD, AMN
152  2014 Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy. X-ALD
153  2014 Monitoring of very long-chain fatty acids levels in X-linked adrenoleukodystrophy, treated with haematopoietic stem cell transplantation and Lorenzo's Oil. HSCT
154  2014 Uridine prevents fenofibrate-induced fatty liver. ACOX1, LCFA
155  2015 A novel ABCD1 mutation detected by next generation sequencing in presumed hereditary spastic paraplegia: A 30-year diagnostic delay caused by misleading biochemical findings. ALD, AMN, HSP, NGS
156  2015 ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy. ABCD1, ALDP, SAHA, X-ALD
157  2015 Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. ABCD1, CNS, i.c.v, rAAV9, X-ALD
158  2015 Metabolic engineering of oilseed crops to produce high levels of novel acetyl glyceride oils with reduced viscosity, freezing point and calorific value. acetyl-TAGs, EaDAcT, TAG
159  2015 Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration. AD, PD
160  2015 Rom2-dependent phosphorylation of Elo2 controls the abundance of very long-chain fatty acids. ---
161  2016 25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome. 25-HC, CCALD, CH25H, LXR, ROS, X-ALD
162  2016 ABC Transporter Subfamily D: Distinct Differences in Behavior between ABCD1-3 and ABCD4 in Subcellular Localization, Function, and Human Disease. ABC
163  2016 Absence of biochemical evidence at an early age delays diagnosis in a patient with a clinically severe peroxisomal biogenesis disorder. ---
164  2016 CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. ALD
165  2016 Familial risk for bipolar disorder is not associated with impaired peroxisomal function: Dissociation from docosahexaenoic acid deficits. ---
166  2016 Infantile Refsum Disease: Influence of Dietary Treatment on Plasma Phytanic Acid Levels. IRD, ZSDs
167  2016 Phenotypic variability in a Tunisian family with X-linked adrenoleukodystrophy caused by the p.Gln316Pro novel mutation. ---
168  2017 Application of a diagnostic methodology by quantification of 26:0 lysophosphatidylcholine in dried blood spots for Japanese newborn screening of X-linked adrenoleukodystrophy. cALD, lysoPC, X-ALD
169  2017 Biochemical and clinical profiles of 52 Tunisian patients affected by Zellweger syndrome. ZS
170  2017 Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. ALD
171  2017 Engineering Rhodosporidium toruloides for the production of very long-chain monounsaturated fatty acid-rich oils. ---
172  2017 Identification and Characterization of Phospholipids with Very Long Chain Fatty Acids in Brewer's Yeast. FA
173  2017 Lipid-induced endoplasmic reticulum stress in X-linked adrenoleukodystrophy. ALD
174  2017 Method for Measurement of Peroxisomal Very Long-Chain Fatty Acid Beta-Oxidation and De Novo C26:0 Synthesis Activity in Living Cells Using Stable-Isotope Labeled Docosanoic Acid. ---
175  2017 Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. AD, ALS, ER, PD, TUDCA, UPR, X-ALD
176  2017 X-linked adrenoleukodystrophy in a chimpanzee due to an ABCD1 mutation reported in multiple unrelated humans. AMN, X-ALD
177  2018 Induction of peroxisomal changes in oligodendrocytes treated with 7-ketocholesterol: Attenuation by alpha-tocopherol. 7-KC
178  2018 Inflammatory profile in X-linked adrenoleukodystrophy patients: Understanding disease progression. X-ALD
179  2018 Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness. GW, GWI, OEA
180  2018 Profiling and Imaging of Phospholipids in Brains of Abcd1-Deficient Mice. X-ALD
181  2018 Sphingolipidomics of Thermotolerant Yeasts. InsP, LCB, MInsPCer, PtdInsCer
182  2018 [Peroxisomal disorders]. ---
183  2019 Application of machine learning algorithms for the differential diagnosis of peroxisomal disorders. AUC, RCDP, X-ALD, ZS
184  2019 Chinese patients with adrenoleukodystrophy and Zellweger spectrum disorder presenting with hereditary spastic paraplegia. ALD, HSP, ZSD
185  2019 Clinical, neuroimaging, biochemical, and genetic features in six Chinese patients with Adrenomyeloneuropathy. X-ALD
186  2019 CRISPR/Cas9-mediated knockout of Abcd1 and Abcd2 genes in BV-2 cells: novel microglial models for X-linked Adrenoleukodystrophy. X-ALD
187  2019 Late onset adrenoleukodystrophy: A review related clinical case report. ---
188  2019 X-linked adrenoleukodystrophy diagnosed in three brothers. HSCT
189  2020 Spastic paraplegia as the predominant phenotype in a cohort of Chinese patients with adrenoleukodystrophy. ALD, HSP
190  2020 Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy. HDAC, VLCFAs